Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
- Bacterial Infection
- Drug Discovery
- Data Management
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 239020
For the Research Program, Licensor agrees to conduct the Research Program in collaboration with the Licensee Institute partner with a goal of discovering, identifying and synthesizing Licensed Compounds for Development by Institute Licensee into one or more Products for commercialization by Licensee, an Affiliate or Sublicensee.
During the Exclusive Screening Period, the Institute Licensee shall have the exclusive right to screen Macrolides provided by Licensor for Antibiotic Activity.
During the Non-exclusive screening period, the Institute Licensee and its Affiliates shall have the non-exclusive right to screen the Macrolides, for any biological activity, in any biological test system for any therapeutic indication.
During the Non-exclusive screening period, the Institute Licensee shall have a non-exclusive right to screen the Aromatic Polyketides for any biological activity in any biological test system for any therapeutic indication.
For the Research Licenses to the Institute Licensee, Licensor grants the Institute Licensee a non-exclusive license, with no right to grant sublicenses, under Licensor Patent Rights and Know-how to make and use methods and materials to carry, out the Research Program during the Research Term.
For the Screening Licenses, Licensor grants to the Institute Licensee the non-transferable licenses, with the right to grant sublicenses to the Institute Licensee Affiliates, under the Licensor Patent Rights and Know-how to conduct screening, an exclusive, worldwide license during the exclusive screening period to use the Macrolides, to conduct screening for Antibiotic Activity;
– a non-exclusive, worldwide license during the non-exclusive screening period (a) to use the Macrolides to conduct screening for Antibiotic Activity; (b) to use the Aromatic Polyketides to conduct screening for any activity; and
– a non-exclusive, worldwide license during the Exclusive Screening Period and Non-exclusive screening period to use the Macrolides to conduct screening for activities other than Antibiotic Activity, excluding any right to screen the Macrolides for Motilide or Anti-inflammatory Activity.
For the Development and Commercialization License Grant, Licensor grants to Licensee a worldwide, exclusive license, with the right to grant sublicenses, under the Licensor patent rights and know-how, to make, use and develop Licensed Compounds, and, to make, have made, use, import, offer for sale, sell and have Sold Products.
Macrolides shall mean 14-membered macrolactones, such as erythromycin, their 3-ketolide congeners, 12-membered macrolactones, 15-membered and 16-membered macrolactones, and other macrolactones or ketolide congeners agreed by the Joint Committee, in each case, obtained by expression of genes from, polyketide, synthase gone clusters including, but not limited to, the erythromycin, rapamycin, tylosin, candicidin, picromycin, or oleandomycin] polyketide, synthase gene clusters, in each case, which are actually utilized in connection with the Research Program that exist in Licensors proprietary compound library as of the effective date; or are synthesized or acquired by or on behalf of Licensor or Licensee in connection with the Research Program.
Motilide Activity shall mean motilin receptor agonist or antagonist activity.
Product shall mean any pharmaceutical product containing a Licensed Compound or a Derivative thereof which is selected for Development and/or marketing by Licensee or its Affiliates or Subllicensees.
IPSCIO Record ID: 240565
Licensor hereby grants to Licensee a non-exclusive, worldwide, royalty-free license, with the right to grant sublicenses to the third party contractors, to use the Screening Libraries in the Screening Field to conduct the Research Program in accordance with this Agreement.
Screening Product means a Product for use as an anti-bacterial agent or anti-fungal agent in each case in the Product Field.
Identified Compound Family means an Identified Compound and all analogs, homologs, derivatives and congeners thereof as determined by the Research Committee according to the procedure set forth, and mutually agreed to in writing by both parties.
Identified Compound(s) means (i) a compound(s) that has Activity against a Target, (ii) that is obtained from a Screening Library and (iii) the chemical structure of which Licensee requests in writing that Licensor identify pursuant to this Agreement.
Exclusive Research Program Patents means all patents and patent applications, both foreign and domestic, including, without limitation, provisionals, converted provisionals, continuations, divisionals or continuations in part, (i) covering Exclusive Research Program Technology; or (ii) that claim methods of making or isolating a compound(s) within an Identified Compound Family, provided that such claimed method of making or isolating is limited only to such compound(s).
Exclusive Research Program Technology means all information, know-how, trade secrets, inventions and data made during the course of the partiesâ€™ performance under the Research Program that are directed to a composition, formulation or use of a compound within an Identified Compound Family. Exclusive Research Program Technology does not include information, know-how, trade secrets, inventions or data applicable to methods of making, separating, or purifying compounds within an Identified Compound Family.
IPSCIO Record ID: 203561
For the research licenses, Licensor grants during the Research Term a worldwide, exclusive, with reserved rights to Licensor, a license, under the Licensor Know-how and Patents as necessary for Licensee to conduct its obligations and tasks under the Research Plan.
For the commercialization license, Licensor grants during the Term of this Agreement a worldwide, exclusive license under the Licensors Know-how and Patents to use, make, have made, market, distribute, promote, offer for sale, sell, export and import Product, including the right to grant sublicenses to Affiliates and Sublicensees.
The oxazolidinone class of antibiotics is a relatively recent addition to the antimicrobial world and have been found to be especially useful in treating infections caused by Gram-positive bacteria.
The patents are for Method For Solid Phase Synthesis of Alcohol Derivatives and Resulting Compositions; and Oxazolidinone Combinatorial Libraries, Compositions and Methods of Preparation.
This application discloses methods for the solid phase synthesis of oxazolidinones; oxazolidinone combinatorial libraries and methods for their synthesis; pharmaceutical compositions comprising bioactive oxazolidinone compounds, including those adapted for oral, topical or parenteral use for the treatment of bacterial infections; and methods of screening combinatorial libraries to detect compounds with activity for treatment of disease states such as inflammation, infection, hypertension, CNS disorders and cardiovascular disorders.
TITLE OXAZOLIDINONE COMBINATORIAL LIBRARIES, COMPOSITIONS AND METHODS OF PREPARATION
This application discloses combinatorial libraries comprising oxazolidinones; methods of preparation of the libraries; biologically active oxazolidinone compositions including compositions for use for the treatment of bacterial infections; and methods of screening combinatorial libraries to detect bioactive compounds useful for treatment of disease states such as inflammation, infection, hypertension, central nervous system disorders and cardiovascular disorders.
TITLE OXAZOLIDINONE COMBINATORIAL LIBRARIES, COMPOSITIONS AND METHODS OF PREPARATION
Biologically active oxazolidinones, libraries and pharmaceutical compositions, and methods of preparation are disclosed, wherein the biologically active oxazolidinones may be used in pharmaceutical applications including use as sedatives, anticonvulsants, muscle relaxants, anti-Parkinson agents, analgesics, antiinflammatories, local anesthetics, muscle contractants, antibiotic, antiviral, antiretroviral, antimalarials, diuretics, lipid regulating agents, antiandrogenic agents, antiparasitics, neoplastics, antineoplastics and chemotherapy agents, as well as for treatment of cardiovascular diseases, central nervous system diseases, cancer, metabolic disorders, infections and dermatological diseases as well as other biological disorders and infections.
IPSCIO Record ID: 222558
For the Collaboration Target-Specific Technology, Licensor grants an exclusive license, exclusive even as to Licensor and its Affiliates, under all of Licensors interest in the Collaboration Target-Specific Technology for any and all purposes in the Territory, including the right to grant sublicenses.
For the Collaboration Platform Technology, upon conclusion of the Collaboration Term, the Parties each grant, to the other a co-exclusive license under their respective interests in the Collaboration Platform Technology in the Territory, as follows the Parties may each use such Collaboration Platform Technology for any and all internal uses, including without limitation, in collaboration with Third Parties for drug discovery.
For the Columbia Sublicense, Licensor grants a non-exclusive sublicense, without the right to sublicense, under the Columbia License, to make, have made, use, offer to sell, sell, import and export Agreement Products in the Territory, including, without limitation, the right to decode Library Compounds.
Product means any Agreement Product or Licensees Product.
Agreement Product shall mean any product containing an Agreement Compound, including, without limitation, products for the therapeutic or prophylactic treatment or prevention of diseases and conditions in human beings or animals.
Licensees Product shall mean any product for the therapeutic or prophylactic treatment or prevention of diseases and conditions in human beings containing a Licensee Compound, provided such Licensee Product is not a Combination Product containing both a Licensee Compound and an Agreement Compound.
Active Compound shall mean a Library Compound that demonstrates activity against a specific Target, which Library Compound was found to have such activity at a concentration set forth in the applicable Collaboration Research Plan during screening of one or more Libraries by Licensor in the conduct of the Collaboration or was found to have such activity during screening by or on behalf of Licensee.
Licensor's combinatorial chemistry technology as an important component in our ongoing efforts to accelerate the drug discovery process and to identify lead compounds for development as new therapeutic entities.'
IPSCIO Record ID: 227289
Screening License – Licensor hereby grants to Licensee a nonexclusive, worldwide, royalty-free license (without the right to sublicense) under the Licensor Patent Rights and other rights in the Licensor Technology to screen Licensor Compounds delivered under the collaboration against Anti-Infective Targets and Anti-Fungal Targets in the Field, but only during the Screening Phase.
Develop and Commercialize License – Licensor hereby grants to Licensee and its Affiliates the following licenses
(i) an exclusive, worldwide license (with the right to sublicense) under the Licensor Patent Rights and other rights in Licensor Technology to conduct development of Licensed Compounds in the Field, including the right to develop Analog Compounds based on Licensed Compounds.;
(ii) an exclusive, worldwide license (with the right to sublicense) under the Licensor Patent Rights and other rights in Licensor Technology to make, have made, use, have used, sell, and import Licensed Compounds and certain identified Analog Compounds, as described below, in the Field; and
(iii) a non-exclusive, worldwide license (with the right to sublicense) under the Licensor Patent Rights and other rights in Licensor Technology to use chemical synthesis methods within the Licensor Patent Rights and Licensor Technology to make and have made Royalty-Bearing Products.
Licensed Compound Se means a set of one or more Licensed Compounds from the same Mapping Array Library that have biological activity for the same Target, as well as any Licensor Analog Compounds of such Licensed Compounds that are synthesized by a party in the course of optimizing those Licensed Compounds.
Patent Rights means any United States and foreign patent application and any divisional, continuation, or continuation-in-part of such patent application (to the extent the claims are directed to subject matter specifically described therein), as well as any patent issued thereon and any reissue or reexamination of such patent, and any foreign counterparts to such patents and patent applications.
IPSCIO Record ID: 249718
(a) the NeoMorph Screening Library,
(b) the NeoMorph Focused Libraries,
(c) ALIS and QSCD,
(d) the Preliminary Compounds,
(e) the Primary Active Compounds,
(f) the Selected Compounds, together with, where applicable, any analogs, derivatives, fragments, sub-cellular constituents or expression products thereof made by Licensor, and
(g) any other tangible materials provided by Licensor to Licensee for use in the conduct of the Programs.
The NeoMorph Screening Library consists of approximately 10,000,000 diverse small organic compounds.
Licensor synthesize small molecule compounds as mixtures in a format that enables ALIS to efficiently screen proteins. Our proprietary NeoMorph library, consisting of over 10 million diverse small molecules, is stored as approximately 5,000 mixtures, each containing approximately 2,000 mass-encoded compounds. We use proprietary software to ensure that each small molecule compound within a mixture can be uniquely identified by its mass. This obviates the need for artificial tagging methods, which adds preparation time and cost, and may interfere with the screening process.
Under this drug discovery collaboration, Licensor agreed to screen a number of proteins supplied to us by Licensee. Licensor maintains the option to develop some or all of the small molecule compounds Licensor identify.